Answers are grounded in this paper and cite their sources.
Background/Objectives: Chronic Chagas cardiomyopathy (CCC), caused by Trypanosoma cruzi (T. cruzi), remains a major public health challenge and a leading cause of heart failure, with this chronic stage representing the period when most patients are diagnosed and require clinical intervention. However, the efficacy of the available parasiticidal drugs, benznidazole (BZL) and nifurtimox during chronic infection is limited and new therapeutic approaches are needed. In this study, we evaluated a novel sequential chemo-immunotherapeutic strategy (BZL → Vac → BZL) designed to shorten benznidazole treatment duration to minimize drug-related adverse effects by leveraging the synergistic potential of both treatments. Methods: BALB/c mice chronically infected with T. cruzi were used as model. A long-term sequential regimen was evaluated and compared 190 days post-infection with uninfected, untreated infected (Tc), monotherapy (BZL or TSNt-ISPA vaccine), and combined (Vac → BZL) controls. The sequential treatment consisted of an initial short cycle of oral BZL, three subcutaneous immunizations with the TSNt-ISPA vaccine, and a final BZL booster. Cardiac parasite load and cytokine expression (qPCR), inflammation and fibrosis (histopathology), electrocardiograms (ECG), specific antibodies (ELISA), and splenic cellular response (flow cytometry) were analyzed. Results: The BZL-Vac → BZL scheme significantly reduced cardiac parasite load, achieving undetectability in some animals. Combined therapies (Vac → BZL and BZL → Vac → BZL) significantly attenuated myocardial inflammation and fibrosis, improving P-wave duration and the QTc interval. The sequential treatment induced a robust Th1-associated humoral response (IgG2a) and a balanced cellular profile, uniquely increasing splenic IL-10-producing CD4+ T cells, TNF-α-producing CD8+ T cells, and cardiac IL-10 and Foxp3 expression. Conclusions: The temporal integration of fractionated benznidazole and TSNt-ISPA immunotherapy protects myocardial integrity and function through an effector immune response under strict regulatory control.
No takes yet. Share an insight, caveat, or question.
Cacik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: